
Chemical and Pharmaceutical Bulletin p. 782 - 786 (1998)
Update date:2022-07-30
Topics:
Martin-Martinez, Mercedes
Ballaz, Santiago
Latorre, Miriam
Herranz, Rosario
Garcia-Lopez, M. Teresa
Cenarruzabeitia, Edurne
Del Rio, Joaquin
Gonzalez-Muniz, Rosario
In order to find new classes of non-peptide cholecystokinin (CCK) ligands, the conformational restriction of a series of weak 3- oxoindolizidine-based CCK antagonists has been both decreased and increased. This tactic yielded a series of monocyclic 2-oxopyrrolidine derivatives 4 with selectivity for CCK-A or CCK-B receptors and with slightly improved binding affinity at the CCK-A receptor subtype with respect to the model 3- oxoindolizidines. In contrast, the incorporation of the Trp residue at the secondary amino group of a pyrrolo[1,2-a]pyrazine template 5, involving a drastic restriction in the conformational flexibility of the molecule, resulted in a series of bicyclic derivatives that did not bind to CCK receptors at concentrations up to 10-5 M.
View MoreCompro Shijiazhuang Fine Chemical Co., Ltd
Contact:0086-311-89689838
Address:Economic and Technological Development Zone of Shijiazhuang,Hebei
Shanghai Science Peptide Biological Technology Co.,ltd
website:http://www.scipeptide.com
Contact:+86-21-51099675
Address:No.8 Changyang Rd
ShangHai Soyoung Biotechnology Inc
website:http://www.soyoungbio.com
Contact:+86-21-69893009
Address:shanghai
JIANGSU GRAND XINYI PHARMACEUTICAL CO.,LTD
website:http://www.xypharm.com/
Contact:+86-515-84383317
Address:Chenli Road,Costal Chemical Area Binhai,Yancheng, Jiangsu,China
Shijiazhuang City Xiehe Pharmaceutical Co., Ltd
Contact:+86-311-80817929
Address:Shangzhuang,Shijiazhuang,China
Doi:10.1080/00958972.2010.548862
(2011)Doi:10.1039/c0cc04677a
(2011)Doi:10.1021/jo980541v
(1998)Doi:10.1021/acschemneuro.6b00181
(2017)Doi:10.1016/j.jorganchem.2016.12.013
(2017)Doi:10.1021/jm000286i
(2000)